Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating tumor DNA-From bench to bedside.

Joline S J Lim1, Filip Janku2, Timothy A Yap2

  • 1Drug Development Unit, Royal Marsden Hsopital, London, UK; Department of Hematology-oncology, National University Cancer Institute of Singapore, Singapore.

Current Problems in Cancer
|April 19, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

JCO precision oncology·2025
Same author

Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics.

Molecular oncology·2025
Same author

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial.

JAMA oncology·2025
Same author

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.

Therapeutic advances in medical oncology·2025
Same author

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same journal

When should the medical oncologist call the surgeon?

Current problems in cancer·2026
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
See all related articles

Circulating tumor DNA (ctDNA) from blood offers a less invasive alternative to tissue biopsies for molecular profiling in cancer. This approach aids in guiding personalized treatment decisions and monitoring drug resistance throughout a patient's cancer journey.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Personalized Medicine

Background:

  • Tumor sampling is crucial for identifying molecular aberrations to guide cancer treatment decisions.
  • Longitudinal tracking of these aberrations can detect drug resistance and inform therapy adjustments.
  • Invasive tumor biopsies pose risks and logistical challenges, driving interest in alternative methods.

Purpose of the Study:

  • To discuss the concept and clinical applications of circulating tumor DNA (ctDNA).
  • To review available technology platforms for ctDNA interrogation.
  • To explore the potential of ctDNA in guiding cancer diagnosis, prognostication, and therapy.

Main Methods:

  • Review of the concept of circulating tumor DNA.
  • Discussion of technology platforms for ctDNA analysis.
Keywords:
CancerCirculating tumor DNA (ctDNA)Liquid biopsy

Related Experiment Videos

  • Examination of current and future clinical applications of ctDNA.

    • Main Results:

    • Circulating tumor DNA (ctDNA) analysis provides a less invasive method for molecular profiling compared to tissue biopsies.
    • ctDNA can be utilized for longitudinal monitoring of cancer over time.
    • Various technology platforms exist for the interrogation of ctDNA.

    Conclusions:

    • ctDNA analysis is a promising tool in personalized medicine, offering a safer alternative to invasive tumor sampling.
    • ctDNA has the potential to guide cancer management from diagnosis through treatment and monitoring.
    • Further integration of ctDNA into clinical practice may significantly improve patient outcomes.